Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma
This is an open-label, phase II study evaluating efficacy and safety of Nab-paclitaxel Combined With Bevacizumab for unresectable Recurrent or metastatic extrapulmonary neuroendocrine carcinoma.
Neuroendocrine Carcinoma
DRUG: Nab-paclitaxel Combined With Bevacizumab
Overall Survival (OS), Duration from the date of initial treatment to the date of death due to any cause, an expected average of 24 months
Overall Response Rate (ORR), Percentage of patients who achieve partial response (PR) or complete response (CR) based on Response Evaluation Criteria In Solid Tumors (RECIST v1.1)., From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months|Duration of Response (DoR), The percentage of patients who achieve complete remission(CR) or partial remission (PR) or stable disease(SD) determined by the RECIST v1.1 criteria., From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months|Progression Free Survival (PFS), A duration from the date of initial treatment to radiographic disease progression or death of any cause, an expected average of 24 months|Disease Control Rate (DCR), Proportion of objective complete response, partial response and stable patients, From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months|Adverse events, Including other occasional or rare AEs, an expected average of 24 months
Nab-paclitaxel Combined With Bevacizumab will be evaluated in participants who have had â‰¥ 1 line of previous treatment. The primary endpoint is the Overall Survival (OS).